Accelerated Pharma (Accelerated Pharma) Interest Expense : $-0.88 Mil (TTM As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Accelerated Pharma's interest expense for the three months ended in Mar. 2017 was $ -0.28 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2017 was $-0.88 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Accelerated Pharma's Operating Income for the three months ended in Mar. 2017 was $ -0.41 Mil. Accelerated Pharma's Interest Expense for the three months ended in Mar. 2017 was $ -0.28 Mil. Accelerated Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Accelerated Pharma Interest Expense Historical Data

The historical data trend for Accelerated Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Interest Expense Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Interest Expense

-0.64

-0.83

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Interest Expense	Get a 7-Day Free Trial			-0.23	-0.23	-0.20	-0.17	-0.28

Accelerated Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88 Mil.

Accelerated Pharma (NAS:ACCP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Accelerated Pharma's Interest Expense for the three months ended in Mar. 2017 was $-0.28 Mil. Its Operating Income for the three months ended in Mar. 2017 was $-0.41 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2017 was $1.23 Mil.

Accelerated Pharma's Interest Coverage for the quarter that ended in Mar. 2017 is calculated as

Accelerated Pharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines